Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Gynecologic 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 881Bortezomib 478Lenalidomide 467Cyclophosphamide 367Melphalan 275Calcium Dobesilate 264daratumumab 240pomalidomide 215carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 68Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 59Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Remote Patient Monitoring × Plasma cell × Clear all
NCT06179888 2026-05-13

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Recruiting
78 enrolled
Plasma cell

Multiple Myeloma

NCT06145581 2026-04-13

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

Mayo Clinic

Phase NA Recruiting
25 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡